Li Kang V, Flores-Bellver Miguel, Aparicio-Domingo Silvia, Petrash Carson, Cobb Hannah, Chen Conan, Canto-Soler M Valeria, Mathias Marc T
CellSight Ocular Stem Cell and Regeneration Research Program, Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, United States.
Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, United States.
Front Cell Dev Biol. 2022 Feb 18;10:813538. doi: 10.3389/fcell.2022.813538. eCollection 2022.
Transplantation of stem cell-derived retinal pigment epithelium (RPE) cells is a promising potential therapy for currently incurable retinal degenerative diseases like advanced dry age-related macular degeneration. In this study, we designed a set of clinically applicable devices for subretinal implantation of RPE grafts, towards the overarching goal of establishing enabling technologies for cell-based therapeutic approaches to regenerate RPE cells. This RPE transplant kit includes a custom-designed trephine for the production of RPE transplants, a carrier for storage and transportation, and a surgical device for subretinal delivery of RPE transplants. Cell viability assay confirmed biocompatibility of the transplant carrier and high preservation of RPE transplants upon storage and transportation. The transplant surgical device combines foldable technology that minimizes incision size, controlled delivery speed, no fluid reflux, curved translucent tip, usability of loading and reloading, and ergonomic handle. Furthermore, the complementary design of the transplant carrier and the delivery device resulted in proper grasping, loading, and orientation of the RPE transplants into the delivery device. Proof-of-concept transplantation studies in a porcine model demonstrated no damage or structural change in RPE transplants during surgical manipulation and subretinal deployment. Post-operative assessment confirmed that RPE transplants were delivered precisely, with no damage to the host retina or choroid, and no significant structural change to the RPE transplants. Our novel surgical kit provides a comprehensive set of tools encompassing RPE graft manufacturing to surgical implantation rendering key enabling technologies for pre-clinical and clinical phases of stem cell-derived RPE regenerative therapies.
移植干细胞来源的视网膜色素上皮(RPE)细胞是一种有前景的潜在疗法,可用于治疗目前无法治愈的视网膜退行性疾病,如晚期干性年龄相关性黄斑变性。在本研究中,我们设计了一套临床适用的设备,用于将RPE移植物植入视网膜下,目标是建立基于细胞的治疗方法的支持技术,以再生RPE细胞。这种RPE移植套件包括一个定制设计的环钻,用于制作RPE移植物;一个储存和运输载体;以及一个用于将RPE移植物递送至视网膜下的手术装置。细胞活力测定证实了移植载体的生物相容性以及RPE移植物在储存和运输后的高保存率。移植手术装置结合了可折叠技术,可将切口尺寸最小化、控制递送速度、无液体回流、弯曲的半透明尖端、可装载和重新装载的可用性以及符合人体工程学的手柄。此外,移植载体和递送装置的互补设计使得RPE移植物能够正确抓取、装载并定向到递送装置中。在猪模型中的概念验证移植研究表明,在手术操作和视网膜下植入过程中,RPE移植物没有受到损伤或结构变化。术后评估证实,RPE移植物递送精确,对宿主视网膜或脉络膜没有损伤,RPE移植物也没有明显的结构变化。我们的新型手术套件提供了一套全面的工具,涵盖了从RPE移植物制造到手术植入的过程,为干细胞来源的RPE再生疗法的临床前和临床阶段提供了关键的支持技术。